Medicon Valley Alliance and PCI would like to welcome you to a Good Morning Meeting 20th of May 2025.
The pharmaceutical industry is undergoing a rapid transformation driven by scientific breakthroughs, evolving regulatory landscapes, and the demand for more targeted, patient-centric therapies. Innovation in the Pharmaceutical World will spotlight key advancements shaping the future of healthcare, from cutting-edge biologics to scalable, integrated supply chains.
This event will feature insights into the development of innovative biologics and targeted therapies, highlighting how precision medicine is revolutionizing treatment strategies. Experts will also explore how to effectively navigate development and manufacturing pathways for Antibody-Drug Conjugates (ADCs), to ensure a successful and phase appropriate approach to clinical trials and beyond. The growing market in Advanced Drug Delivery (ADD) platforms will also be addressed, where we will examine supply chain considerations for drug-device combination products, emphasizing strategies to build low-risk, highly scalable models that support product success from clinical development to commercial launch.
Date: Tuesday 20th of May 2025
Time: 8:30 – 11:00
Venue: Medicon Valley Alliance, Arne Jacobsens Allé 15, 2300 Copenhagen S, Denmark – Hub 2
Program
| 8:30 | Networking, registration and light breakfast |
| 9:00 | Welcome and introduction to Medicon Valley Alliance David Munis Zepernick, Director, Member Engagement & Communication, Medicon Valley Alliance |
| 9:05 | Considerations for building a Low-Risk, Highly Scalable Supply Chain for Drug-Device Combination Products Paul Smallmann, Senior Director, Global Technical Sales |
| 9:40 | How to effectively navigate development and manufacturing pathways for Antibody-Drug Conjugates (ADCs) Laurent Thouvais, Senior Director, Development and Manufacturing Global Business Development |
| 10:10 | Conclusions: A quick recap of the key learning points |
| 10:20 | Q&A session |
| 10:35 | Networking |
| 11:00 | End of Good Morning Meeting |
Speakers
 |
Laurent Thouvais, Senior Director, Development and Manufacturing Global Business Development
Laurent Thouvais is a seasoned professional in the Biologics CGT CDMO space with over two decades of experience in Testing, Development, & Manufacturing strategy. As Senior Director of Global Business Development at PCI Pharma Services, Laurent plays a critical role in supporting the end-to-end clinical and commercial supply needs of complex therapies, with a particular focus on Antibody-Drug Conjugates (ADCs) and other targeted therapies. |
 |
Paul Smallman, Senior Director, Global Technical Sales
Paul Smallman is a senior technical leader at PCI Pharma Services, bringing over 30 years of expertise in pharmaceutical packaging and drug delivery systems. At PCI, Paul plays a key role in delivering innovative technical solutions across the entire drug product lifecycle—from stability studies and clinical trial supplies to full-scale commercial launch. He leads cross-functional technical teams to ensure the successful design, development, and implementation of packaging formats and processes that meet the unique needs of each client. Partnering with a wide range of small, mid-size, and large biopharmaceutical companies, Paul has a proven track record of directing complex projects from concept to commercialization, helping to bring life-changing treatments to patients around the world. |
| Organized by | In collaboration with |
 |
 |